Evolving Standards of HER2-Positive Breast Cancer
Sunil Verma, MD, MSEd, FRCPC, discusses evolving standards of early stage HER2-positive breast cancer.
Targeting HER2 in Patients With Early-Stage Disease
Sunil Verma, MD, MSEd, FRCPC, associate professor, University of Toronto, chair, Breast Medical Oncology, Sunnybrook Odette Cancer Centre, discusses targeting HER2 in patients with early-stage breast cancer.
HER2 Testing and the Utility of Ki67
Sunil Verma, MD, MSEd, FRCPC, associate professor, University of Toronto, chair, Breast Medical Oncology, Sunnybrook Odette Cancer Centre, comments on HER2 testing and the utility of Ki67.
Advances in the Treatment of Metastatic HER2-Positive Breast Cancer
Sunil Verma, MD, MSEd, FRCPC, University of Toronto, Breast Medical Oncology, Sunnybrook Odette Cancer Centre, discusses advances in the treatment of patients with metastatic HER2-positive breast cancer.